ADARx Pharmaceuticals Inc(ADRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 59.08% | Shs Outstand | 106.8M | Perf Week | -0.11% |
| Market Cap | 1.96B | Forward P/E | - | EPS next Y | - | Insider Trans | 8.56% | Shs Float | 45.4M | Perf Month | - |
| Enterprise Value | 1.90B | PEG | - | EPS next Q | -0.82 | Inst Own | - | Short Float | 2.56% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 12.57% | Short Ratio | 1.35 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 1.16M | Perf YTD | -20% |
| Book/sh | -2.35 | P/C | 4.59 | EPS past 3/5Y | - | ROE | - | 52W High | -23.83% ($23.21) | Perf Year | - |
| Cash/sh | 3.85 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 6.44% ($16.61) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.28% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.98 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 41.1 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.98 | Sales Q/Q | - | SMA20 | -3.7% ($18.36) | Beta | - | Target Price | $34.25 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/09/02 | SMA50 | -3.7% ($18.36) | Rel Volume | 0.21 | Prev Close | $17.13 |
| Employees | - | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | - | SMA200 | -3.7% ($18.36) | Avg Volume(3M) | 0.86M | Price | $17.68 |
| IPO | 2026/9/25 | Option/Short | No/Yes | Trades | 2448 | Volume | 181,506 | Change | 3.21% |
🧬 리보핵산 간섭 방식으로 질환 유발 단백질의 생성을 줄이는 신약을 개발하는 임상 단계 바이오테크 기업입니다. 2019년 설립되어 미국 캘리포니아 샌디에이고에 본사를 두고 있으며, 간 표적 프로그램과 지방·신경 등 간 외 표적 프로그램을 나란히 개발하고 있습니다.
Over the past 1 year, on the lower side
24% below its 1-year high.
Traded less than usual. That is 21% of its average volume.
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Shareholder Composition Guide
Tap to view numbers
It ranks #98 of 594 in the industry
Based on market cap of $2B.
ADRX#98 ADARx Pharmaceuticals Inc $2B PER - 
BRVE#99 Braveheart Bio Inc $2B PER - 
XNCR#100 Xencor Inc $2B PER - 
SRPT#101 Sarepta Therapeutics Inc $2B PER - 
SEPN#102 Septerna Inc $2B PER - 
FAQ
What kind of company is ADRX?
ADRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ADRX?
The market cap of ADRX is approximately $2.0B, ranking 2,068 within its sector.
What is the 52-week high and low for ADRX?
ADRX has recorded a 52-week high of $23.21 and a low of $16.61.
